Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Exclusion Criteria

• •Central nervous system involvement；
• •Simple extramedullary leukemia or simple extramedullary recurrence；
• •Received hematopoietic stem cell transplantation within the last 3 months and had graft-versus-host disease (GVHD) in the last 2 weeks, requiring immunosuppressive agents；
• •Treated with high-dose corticosteroids in the last 1 week；
• •Allogeneic cell therapy, major surgery, and live or attenuated vaccine had been received within 4 weeks prior to CAR NK-CD19 infusion；
• •Had received other antitumor therapy or had an uncontrolled infection within 2 weeks prior to CAR NK-CD19 infusion；
• •Systemic steroids were used within 3 days before CAR NK-CD19 infusion；
• •Toxicity caused by previous treatment do not fully recover or do not stabilize to grade 1；
• •Concomitant autoimmune diseases, central nervous system diseases, other active malignancies, infectious diseases, severe cardiovascular diseases, etc；
• •Known allergies to study drugs or drugs that may be used in the study；
• •Other conditions determined by Investigator which are not suitable for participation in the study